Background: Traumatic brain injury (TBI) is a common occurrence following gastroin-
pathologically through multiple interacting mechanisms. Accounting for the fact that TBI is associated with these mechanisms, it is important to explore neuroprotective agents that may attenuate TBI.
Gastrointestinal dysfunction is one of several complications in patients with TBI.
8 TBI can result in increased intestinal permeability and structural and functional damage of the gastrointestinal tract. 9 There is evidence that intestinal bacteria are directly involved in the development of TBI. 10 The gut microbiota is an important internal environment factor that regulates the bidirectional commutation that underlies the gut-brain axis. 11 Indeed, microbiota dysfunction is linked to a variety of disorders such as experimental stroke, 12, 13 Parkinson's disease, 14 and Alzheimer's disease. 15 The gastrointestinal hormonal signaling pathway is one part of the complex network of communication between gut microbiota and the brain.
Glucagon-like peptide-1 (GLP-1) is released by intestinal L-cells, which predominantly localized in the colon and ileum. Gut microbial changes were associated with variations of GLP-1 content. 16 Gut microbiome are in direct contact with L-cells in the intestine. Thus, it is
clear that different microbial populations may react to local environmental cues that can be regulated by the gut microbiota. 17 While the composition of the gut microbiota varies greatly among individuals, alterations to the balance of common gut microbes may affect production of the short-chain fatty acids (SCFAs) butyrate, propionate, and acetate, 18 which are products of intestinal bacterial fermentation.
The levels of SCFAs in the intestinal tract are influenced by the microbial composition. is found throughout the central nervous system (CNS), and GLP-1 signaling is implicated in the regulation of a variety of CNS functions, including neurotrophic and neuroprotective effects. 22 Recent studies have shown that the injectable GLP-1 analog, liraglutide, significantly improved outcomes after severe brain trauma in mice, 23 mitigating cognitive impairments after mild TBI in a mouse weight-drop model, 24 which could cross the BBB to exert anti-inflammatory effects on cerebral endothelial cells 25 and to prevent injury-induced changes in gene expression, including pathways associated with oxidative stress and neuroinflammation. 26 GLP-1 is considered one of the chemical mediators that link the gut-brain axis. GLP-1 can engage multiple kinase signaling cascades including phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), protein kinase A (PKA), and extracellular signal-regulated kinase 2 (ERK2). 27, 28 Therefore, modulating the gut microbiome by promoting interactions through the use of probiotics could increase GLP-1 secretion and enhance its beneficial effects.
Clostridium butyricum (Cb) is a butyrate-producing probiotic and an effective agent known for its effects on intestinal bacteriarelated diarrhea. In our previous studies, it was found that Cb is effective in the treatment of vascular dementia 29 and diabetes combined with cerebral ischemia. 13 Our previous studies showed that
Cb can produce a large amount of SCFA butyrate in the gut and exert anti-apoptosis and antioxygenation in vascular dementia animal models, which may have beneficial effects on host brain injury. 30 These effects of Cb can mainly be explained by its ability to increase the production of butyrate and the secretion of the gut hormone GLP-1. 31 Although the ability of Cb to attenuate neuroinflammatory responses and apoptosis and to promote GLP-1 have been separately reported in different experimental models, the effects of Cb on GLP-1 secretion and production have not been clarified in a TBI animal model.
In this study, we provide evidence supporting Cb as a treatment for and management strategy against TBI. We examined the hypothesis that Cb can exert neuroprotection against neurological dysfunction, brain edema, neurodegeneration, and BBB impairment in a mouse model of TBI, which were associated with an increase in the levels of GLP-1 via gut-brain axis. and administered orally at a concentration of 10 9 CFU/day/mice as described previously.
| MATERIALS AND METHODS

| Animal and bacteria preparation
13,30
| Induction of TBI
The TBI mouse model was induced using a modified weight-drop impact head injury, as previously described 32, 33 and as in our previous study. 34 Briefly, mice were anesthetized with 3.5% chloral hydrate via the peritoneum and fixed on an operating table. A midline longitudinal
Key Points
• Clostridium butyricum significantly improved neurological dysfunction, brain edema, neurodegeneration, and BBB impairment.
• Clostridium butyricum-treated mice showed increased the secretion of intestinal GLP-1 and upregulated expression of cerebral GLP-1R.
• Our findings demonstrated the neuroprotective effect of Clostridium butyricum in TBI mice and the involved mechanisms were partially attributed to the elevating GLP-1 secretion through the gut-brain axis.
incision was made on the top of the skull and a bone window 3 mm in diameter was created to expose dura mater 2 mm rightward of the sagittal suture and 3 mm posterior to the coronal suture. A 20-g weight was dropped from a height of 20 cm onto the target area, after which the scalp wound was closed using standard suture material.
Placebo animals underwent the same procedures but did not undergo the weight-drop impact head injury.
| Experimental design
After acclimation for 1 week, the animals were randomly divided into 
| Behavioral assessment
Post-trauma neurological deficits were evaluated in a blinded fashion using a 10-point NSS, as described previously. 35 This assessment is composed of 10 individual tasks that are used to assess motor functions, balance, and alertness of the mice. One point is awarded for failing to fulfill an individual task and no point for succeeding. A higher score indicates a more severe neurological deficit. The test was performed at 1, 4, 24 hour, 4, 7, 10 and 14 days after trauma.
| Brain water content
Brain water content was measured according to a previous study 36 with a minor modification. In brief, the mice were decapitated under deep anesthesia 24 hour after trauma. Brain samples were immediately harvested, and the injured hemispheres without the cerebellum or the olfactory bulb were accurately weighed (wet weight). Then, the brain samples were dried in a desiccating oven at 90°C for 48 hour and weighed again (dry weight). The percentage of brain water content (%)
was calculated according to the wet-to-dry ratio ([wet weight -dry weight]/wet weight × 100).
| Fluoro-Jade C staining
Fluoro-Jade C staining is a reliable marker that exhibits a great affinity for degenerating neurons and has been widely applied in the study of brain trauma. The Fluoro-Jade C staining procedure was performed as described in our previous study. 34 At 24 hour post-trauma, mice
were euthanized with an overdose of 3.5% chloral hydrate and then transcardially perfused with 40 mL 4% paraformaldehyde (PFA). Brain 
| EB assay
BBB permeability was assessed by measuring the intracephalic amount of Evans blue (EB) dye, as previously described. 34 EB solution (2% in saline, 3 mL/kg body weight) was slowly injected into the tail vein at 24 hour following TBI and then circulated for 60 minutes. After being anesthetised, the mice were perfused through the left ventricle of the heart with cold saline to remove the intravascular dye. Next, the brains were removed, photographed and weighted. Then, the ipsilateral hemispheres were homogenized in formamide, soaked for 72 hour at 37°C, and centrifuged for 20 minutes at 12 000 g. The supernatant was collected and its optical density (OD) was recorded using an ultraviolet spectrophotometer at a wavelength of 625 nm. Calculations were based on external standard readings (80 μg/mL of EB dissolved in saline with eight serial dilutions). The amount of EB in the test sample was expressed in ng/g wet brain tissue. A higher amount of dye in brain tissue represents a greater vascular permeability and more severe BBB impairment. 
| Immunohistochemistry and immunofluorescence
| Western blot analysis
At 14 days post-trauma, the mice were sacrificed and brain and colon samples were quickly removed. The ipsilateral cortex around the injured site and proximal colon were isolated and stored at −80°C until further use. The samples were homogenized using a hand- 
| Statistical analysis
Data of the NSS values were analyzed by two-way analysis of variance (treatment × time, ANOVA) with repeated measures followed by the Bonferroni test. All other data were analyzed by one-way ANOVA. All data are presented as the mean ± standard error of the mean (SEM). The significant difference threshold was set at P = .05.
Statistical analysis was performed using SPSS statistics V19.0 software.
| RESULTS
| Cb treatment improved neurological deficits in TBI mice
NSS was evaluated at 1, 4, 24 hour, 4, 7, 10, and 14 days after brain trauma. The results are shown in Figure 2 . There was a significant increase in NSS among all the groups subjected to brain trauma, except the sham group. NSS was significantly decreased in the Cb-treated group compared to the TBI group at 4 days (P < .01), 7 days (P < .01), 10 days (P < .01), and 14 days (P < .05) post-trauma, suggesting that Cb treatment effectively alleviated neurological deficits in TBI mice.
| Cb treatment ameliorated brain edema in TBI mice
Brain edema was measured by brain water content at 24 hour posttrauma. As shown in Figure 3A , brain water content increased in TBI mice compared to that of the sham group (P < .05), while Cb treatment led to a significant decrease in brain water content (P < .05).
| Cb treatment delayed neuronal degeneration in TBI mice
The results are shown in Figure 3B . Fluoro-Jade C-positive cells (FJC+) labeling of neurons in the sham group was non-existent.
Fluoro-Jade C-positive cells (FJC+) were increased in the cortical injury area and in an adjacent location in the TBI group. In contrast, the number of FJC+ cells in Cb-treated mice was significantly less than in the TBI group.
As shown in Figure 4 , the neurons in the TBI group were loose in arrangement and some of them were absent, but in the Cb treatment group, the Nissl's bodies increased. In brief, Cb treatment attenuated the pathologic changes and neuronal loss in TBI mice.
| Cb treatment ameliorated BBB impairment in TBI mice
Representative images and quantitative evaluation of EB extravasations in three groups are shown in Figure 5A -E. The amount of EB dye in the TBI group (P < .01) was significantly increased compared to that in the sham group, indicating brain barrier impairment. However, the Cb group showed a significant decrease in EB extravasations (P < .01) compared to the TBI group. This effect was confirmed by WB, which revealed that levels of occludin and ZO-1 in the TBI group were markedly higher compared to the sham group. Cb treatment significantly increased expression of the occludin and ZO-1 proteins (occludin: P < .01 and ZO-1: P < .01, Figure 6D -F).
| Cb treatment ameliorated neuronal apoptosis in TBI mice
We measured the expression of apoptosis-related protein markers at 14 days post-trauma. Compared with the sham group, the ratio of p-Akt/ Akt was significantly reduced in the TBI group (P < .001, Figure 7A and B). In contrast, the ratio of p-Akt/Akt in the Cb-treated mice was significantly higher when compared with the TBI group (P < .05, Figure 7A and B), suggesting that Cb treatment could activate Akt. Bcl-2 expression was lower in the TBI group than in the sham group 24 hour after TBI but was elevated after Cb treatment ( Figure 7C and D) . Bax levels were elevated in the TBI group and were reduced after treatment with Cb ( Figure 5C and D). The ratio of Bcl-2/Bax was significantly lower in the TBI group compared with the sham group (P < .001, Figure 7C and D). These data demonstrate that Cb activated the PI3K/Akt pathway and inhibited neuronal apoptosis in TBI mice.
| Cb treatment decreased the colonic IL-6 level and ameliorated gut barrier impairment
Inflammatory cytokines exacerbate GI damage after TBI. The level of colonic IL-6 in TBI mice was significantly higher than the sham group, while Cb treatment resulted in a significant decrease (P < .05, Figure 8A ). In addition, d-lactate levels in the TBI group were significantly higher compared with the sham group (P < .01, Figure 8B ).
Treatment with Cb resulted in lower d-lactate levels than in the TBI group (P < .05, Figure 8B ). 
| Cb increased the levels of GLP-1 in the colon and upregulated GLP-1R expression in the brain
As shown in Figure 9C , the level of GLP-1 protein was measured by immunohistochemistry. The TBI group had a lower level of GLP-1 than the sham group. However, the level of colonic GLP-1 in mice treated with Cb was higher than in the TBI group.
The level of GLP-1R was measured by western blot at 14 days posttrauma. The level of GLP-1R in the brain was remarkably decreased in the TBI group compared with the sham group (P < .01, Figure 9A and B), whereas Cb treatment (P < .01, Figure 9A and B) resulted in a significant increase, suggesting that Cb treatment could activate cerebral GLP-1R protein in the TBI mice.
| DISCUSSION
A number of studies have shown that TBI are associated with profound changes in gut dysfunction. 9, 38 Our previous studies have confirmed that Cb is effective in the treatment of brain disorders, 13, 29 by virtue of producing a large amount of butyrate. 30 These effects of Cb can be mainly explained by its ability to increase the secretion of gut hormones GLP-1. 31 However, mechanistic insights Neurological deficits are often the cause of disability after TBI. Our experiment used a mouse model in which TBI was induced with the weight-drop method, which frequently resulted in cortical contusion and a series of neurological impairments. 39 In our previous studies, Cb treatment was shown to potentially attenuate cognitive disorder in mice. [40] [41] [42] Consistent with our present study, Cb treatment significantly ameliorated TBI-induced neurological deficits. At the same time, morphological changes in the lesioned brain were likely to be parallel to alterations in behavior. Neuronal death is a cause of clinical deterioration and poor outcome in TBI. 43 Focal cortical injury is associated with the delayed death of neurons, likely due to retrograde damage of cortical projections. We analyzed Fluoro-Jade C positive (FJC+) cells, which are used as a reliable indicator of degenerating neurons, after TBI. 44 There was an effect of Cb treatment when administered to FJC+ cells after injury in mice.
Cerebral edema peaks within the first 24-72 hour after TBI 45 and is considered a primary causal factor of neuronal injury and neurological deficits after TBI. In this study, Cb treatment decreased the water content in the 24 hour period after trauma. This indicates that Cb prevents brain endothelial barrier dysfunction and suggests that the reduction in brain water content is at least partially due to reduced vasogenic edema. Although the mechanisms that cause post-TBI brain edema have not been fully elucidated, disruption of the BBB is considered a major cause of brain edema and subsequent brain injury.
The BBB, a physical barrier separating brain extracellular fluid,
plays an important role in maintaining the homeostasis of the brain. Increases in TJ protein levels are beneficial for the integrity of the BBB. 49 Protection against BBB-integrity damages induced by TBI is probably achieved through the recovery of TJ proteins. 50 In this study, Cb treatment improved BBB impairment induced by TBI in mice.
Thus, it is likely that the post-TBI reductions in BBB permeability and brain edema demonstrated in the present study are related to the anti-apoptosis properties of Cb. Neuronal apoptosis, which is coincident with the development of TBI, plays an important role in brain injury pathogenesis and may represent a hopeful target for treatment.
The Akt pathway, a central mediator regulating neuronal growth and survival metabolism, 51 has been shown to be involved in the pathogenesis of neuron death and neurological outcome after cerebral contusion in mice. 52, 53 Our results showed that C. butyricum treatment could activate Akt in TBI mice. The activation of Akt can regulate downstream targets, such as Bcl-2 and Bax, which play fundamental roles in the development of TBI. 54 Our result showed that C. butyricum treatment significantly increased the level of Bcl-2 and decreased the level of Bax in TBI mice. Moreover, our previous study also found that Cb is able to exert neuroprotective effects against I/R injury mice through an increase of the Bcl-2/Bax ratio after C. butyricum pretreatment. 12 Taken together, these results suggest that Cb treatment could exert an anti-apoptotic effect via the Akt pathway in TBI mice. Gut microbiota dysfunction is linked to brain disorders.
Accumulating evidence has shown that TBI is a common occurrence following GI dysfunction, along with the secretion of proinflammatory cytokines, degradation of intestinal TJ proteins, 55, 56 and increase in intestinal permeability. 57, 58 Previous studies have The level of SCFAs in the GI may change along with the occurrence of intestinal dysbiosis. 62 Cb treatment could produce abundant butyrate from the fermentation of fibers 63 and result in increased butyrate levels in the colon. Furthermore, butyrate could bind to the G-protein-coupled receptors GPR41 and GPR43 and stimulate gut hormone production in the colon and associated microbial activity with gut L-cells. 31 GLP-1R is widely expressed in the brain, specifically throughout the cerebrum, including the cerebral cortex, hippocampus, and substantia nigra. activating GLP-1R in the brain. Our hypothesis regarding this neuroprotective mechanism is presented in Figure 10 . However, there are also some limitations. Neuropeptide and metabolic parameters other than butyrate and GLP-1 were not measured, so we are not able to say which one changed initially and whether or not the Cb treatment caused these changes. A further study to investigate this potential mechanism is necessary.
In conclusion, our findings demonstrated the neuroprotective effect of Clostridium butyricum in TBI mice and the involved mechanisms were partially attributed to the elevating GLP-1 secretion through the gut-brain axis. Our current studies possibly offer an intriguing opportunity of treatment of TBI patients.
